Skip to main content

Advertisement

Table 17 Descriptive reports of adverse outcomes leading to withdrawal from the trial

From: Screening for thyroid dysfunction and treatment of screen-detected thyroid dysfunction in asymptomatic, community-dwelling adults: a systematic review

Author (Sample size (treatment vs. control) Results Descriptive reports of adverse outcomes (results continued)
Liu et al. [64]
(136; 68 vs. 68)
Control group (0; 0.0% vs. treatment group (1; 1.5%) OR: 3.04 (95% CI 0.12–76.06); p ≥ 0.05
Absolute value (range): 0 fewer per 1000 (from 0 fewer to 0 fewer)
Adverse reaction from treatment requiring withdrawal from the trial was mild paroxysmal supraventricular tachycardia.
Parle et al. [71]
(94; 52 vs. 42)
Control group (6; 14.3% vs. treatment group (5; 9.6%) OR: 0.64 (95% CI 0.18–2.26); p ≥ 0.05
Absolute value (range): 46 fewer per 1000 (from 114 fewer to 131 more)
The side effects resulting in withdrawal from the trial were not described.
Teixeira et al. [74, 75]
(60; 35 vs. 25)
Control group (0; 0.0% vs. treatment group (2; 5.7%) OR: 3.81 (95% CI 0.17–82.80); p ≥ 0.05
Absolute value (range): 0 fewer per 1000 (from 0 fewer to 0 fewer)
Adverse events requiring withdrawal from the trial included developing “hashitoxicosis” while on levothyroxine therapy and symptomatic tachycardia
Zhao et al. [77]
(369; 210 vs. 159)
Control group (0; 0.0%) vs. treatment group (0; 0.0%) No withdrawals due to adverse effects were reported in either the control or treatment groups.